> The company will proceed slowly, says Sharon Rosenzweig-Lipson, chief scientific officer at the company, treating up to 12 people with a specific type of glaucoma, and then up to 6 people with another condition, called NAION, that causes acute optic nerve damage. The genes will be regulated by a genetic switch that turns them on only when participants take a certain antibiotic.
1 comment
> The company will proceed slowly, says Sharon Rosenzweig-Lipson, chief scientific officer at the company, treating up to 12 people with a specific type of glaucoma, and then up to 6 people with another condition, called NAION, that causes acute optic nerve damage. The genes will be regulated by a genetic switch that turns them on only when participants take a certain antibiotic.